A CONSULTANT pathologist who has pioneered the use of AI software to help diagnose prostate cancer, is spearheading another surge into what has been termed “computational pathology”.

Dr Muhammad Aslam and his colleague Dr Anu Gunavardhan have been using the programme to help diagnose breast cancers.

The application, called the Galen platform and developed by Ibex Medical Analytics, has been piloted within Betsi Cadwaladr University Health Board (BCUHB) and the team is the first in the UK to use it clinically to assist in breast cancer diagnosis.

Dr Aslam believes this new clinical use could herald the "dawning of a new era" in cancer diagnostics, as breast cancer treatment requires quick and accurate testing in order to get more successful outcomes for patients.

“We are at the crossroads of an exciting new world and we are at the forefront within Betsi Cadwaladr,” he said.

“With the backlogs we have in the NHS it’s more important than ever to diagnose more quickly and more accurately.”

In Dr Aslam’s previous trial, using it as a prostate cancer diagnostic tool, the programme looked at 1,600 biopsies and diagnosed 13 per cent more cancers than without the AI help.

In the clinical setting, it is not only diagnostic cancer markers being sought, but prognosis markers, which show which treatments or combinations of treatments will be effective.

Streamlining the system of diagnosis is paramount for the team because of the various kinds of breast cancer, which require a variety of treatments.

Dr Gunavardhan, the lead breast pathologist for BCUHB and the Quality Assurance Pathologist for Breast Test Wales, said: “We need to get the results as quickly as possible, as there is lots of anxiety for the patients.

“Our national targets are to get diagnoses back in three days and decide which treatment in seven days. We have prioritised breast cancers.

“We don’t always have enough staff to give this service, so we were looking at how this programme could help us.”


The Galen platform gains knowledge as it goes. Pathologists will check the suspected results for accuracy and the system learns from their input for future tests.

Dr Gunavardhan, who is also chair of Welsh regional council of Royal College of Pathologists, added: “It’s not difficult to diagnose cancer but then we need companion biomarkers to decide what treatment the patient gets.

“The biomarkers, the hormone receptors which mark the cancer, decides which treatment will be given.”

“Dr Gunavardhan’s role is to see if this AI software can help to make the process lean,” said Dr Aslam.

“If the sample pathway from biopsy to definitive diagnosis with biomarkers can be shortened and made efficient, the multidisciplinary team can make the treatment decision without delay.”

Dr Aslam believes it should be called “assistive intelligence” rather than artificial intelligence because a clinician will always be needed to give the final say on diagnoses.

The breast project has benefited from almost £100,000 of funding from the Moondance Foundation and the prostate project was supported by the Small Business Research Initiative Wales.